0
7.4.4.3.1 Summary of evidence and recommendations for targeted therapy in papillary metastatic RCC
Summary of evidence   LE
Sequencing systemic therapy
Nivolumab plus ipilimumab was associated with 46% grade 3–4 toxicity and 1.5% treatment-  1b  related deaths. Tyrosine kinase inhibitor-based IO combination therapies were associated with   grade 3–5 toxicity ranging between 61–72% and 1% of treatment-related deaths.
